Tema腫瘤學主動型ETF CANC 深 滬
交易中 01-29 09:47:40 美东时间
36.14
+0.210
+0.58%
華盛通- 最 高36.14
- 今 開36.14
- 成交量 2939股
- 最 低 36.14
- 昨 收 35.93
- 總市值 1.03亿
- 52周最高 37.51
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 20.0759
- 委 比 0.00%
- 總股本 285.00万
- 歷史最高 37.51
- 量 比 31.72
- 振 幅 0.00%
- 歷史最低 20.0759
- 每 手 1
- 風險率 4.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Rhythm Biosciences Secures Strategic Us Partnership With Cancer IQ
BRIEF-Rhythm Biosciences Secures Strategic Us Partnership With Cancer IQ Jan 28 (Reuters) - Rhythm Biosciences Ltd RHY.AX : SECURES STRATEGIC US PARTNERSHIP WITH CANCER IQ Further company coverage: RHY.AX (( Reuters.Briefs@thomsonreuters.com ;))
01-28 09:37
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results Jan 21 (Reuters) - Gilead Sciences Inc GILD.O : NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PHASE 3 ASCENT-04/KEYNOTE-D19 RESULTS SUPPORTING TRODELVY® PLUS KEYTRUDA® AS A POTENTIAL NEW STANDARD OF CARE IN FIRST-LINE
01-22 06:18
BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers Jan 21 (Reuters) - Actuate Therapeutics Inc ACTU.O : ACTUATE THERAPEUTICS ANNOUNCES PLANS TO EXPAND CLINICAL PIPELINE, ADVANCING ELRAGLUSIB TABL
01-21 21:46
Tema Oncology ETF declares $0.0196 dividend
Tema Oncology ETF (CANC) declares $0.0196/share annual dividend. Payable Dec. 11; for shareholders of record Dec. 10; ex-div Dec. 10. See CANC Dividend Scorecard, Yield Chart, & Dividend Growth. More ...
2025-12-10 22:30
